Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.6
5.4
Journals
Marine Drugs
Special Issues
The Application of Marine Alkaloids and Related Analogues
share announcement

The Application of Marine Alkaloids and Related Analogues

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (31 October 2020) | Viewed by 3428

Special Issue Editors

Prof. Dr. Patrizia Diana

E-Mail Website
Guest Editor
Department of Biological Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi, 32-90123 Palermo, Italy
Interests: marine alkaloids; heterocycles; drug discovery; synthesis; bioactive compounds; antitumor activity; antibiofilm activity; and kinase inhibitors
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Gunhild von Amsberg

E-Mail Website
Guest Editor
Laboratory of Experimental Oncology, Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald-Tumorzentrum and Martini Clinic, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Interests: Marine Alkaloids; Marine Sediment; Marine-Derived Fungus

Special Issue Information

Dear Colleagues,

The marine environment is an inestimable source of novel chemical entities that have shown potential as bioactive drugs. In fact, many marine-derived molecules, with their wide range of biological activities, find different applications as antitumor, anti-inflammatory, antibacterial, and antiviral agents. In particular, marine alkaloids represent a very promising class of compounds due to their potent activities and their extensive structural heterogeneity. The success obtained so far, which is based on a very limited investigation of both deep-sea organisms and marine microorganisms, suggests a high potential for further discovery of new alkaloid drugs.

This Special Issue, dedicated to the "The Application of Marine Alkaloids and Related Analogues”, aims to present an updated overview and to emphasize the importance of the study of marine-derived alkaloids, reporting new results about their isolation, structural characterization, chemical synthesis, biological and pharmacological evaluation. As the Guest Editors, we invite scientists in the fields of chemistry, biochemistry, pharmacology, and toxicology to submit articles on their most recent work.

Prof. Dr. Patricia Diana
Prof. Dr. Gunhild von Amsberg
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Biological activity
  • Marine Organisms
  • Computational studies
  • Alkaloids synthesis
  • Drug delivery

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 3308 KiB  
Article
A Marine Alkaloid, Ascomylactam A, Suppresses Lung Tumorigenesis via Inducing Cell Cycle G1/S Arrest through ROS/Akt/Rb Pathway
by Lan Wang, Yun Huang, Cui-hong Huang, Jian-chen Yu, Ying-chun Zheng, Yan Chen, Zhi-gang She and Jie Yuan
Mar. Drugs 2020, 18(10), 494; https://doi.org/10.3390/md18100494 - 27 Sep 2020
Cited by 11 | Viewed by 2941
Abstract
Ascomylactam A was reported for the first time as a new 13-membered-ring macrocyclic alkaloid in 2019 from the mangrove endophytic fungus Didymella sp. CYSK-4 from the South China Sea. The aim of our study was to delineate the effects of ascomylactam A (AsA) [...] Read more.
Ascomylactam A was reported for the first time as a new 13-membered-ring macrocyclic alkaloid in 2019 from the mangrove endophytic fungus Didymella sp. CYSK-4 from the South China Sea. The aim of our study was to delineate the effects of ascomylactam A (AsA) on lung cancer cells and explore the antitumor molecular mechanisms underlying of AsA. In vitro, AsA markedly inhibited the cell proliferation with half-maximal inhibitory concentration (IC50) values from 4 to 8 μM on six lung cancer cell lines, respectively. In vivo, AsA suppressed the tumor growth of A549, NCI-H460 and NCI-H1975 xenografts significantly in mice. Furthermore, by analyses of the soft agar colony formation, 5-ethynyl-20-deoxyuridine (EdU) assay, reactive oxygen species (ROS) imaging, flow cytometry and Western blotting, AsA demonstrated the ability to induce cell cycle arrest in G1 and G1/S phases by increasing ROS generation and decreasing of Akt activity. Conversely, ROS inhibitors and overexpression of Akt could decrease cell growth inhibition and cell cycle arrest induced by AsA. Therefore, we believe that AsA blocks the cell cycle via an ROS-dependent Akt/Cyclin D1/Rb signaling pathway, which consequently leads to the observed antitumor effect both in vitro and in vivo. Our results suggest a novel leading compound for antitumor drug development. Full article
(This article belongs to the Special Issue The Application of Marine Alkaloids and Related Analogues)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop